Atrial Fibrillation: Unanswered Questions and Future Directions

Vivek Y. Reddy

doi:10.1016/j.mcna.2007.09.008

Atrial Fibrillation: Unanswered Questions and Future Directions

Vivek Y. Reddy

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

Just more than a decade ago, Haissaguerre and colleagues provided the seminal demonstration of the role of pulmonary vein triggers in the pathogenesis of atrial fibrillation (AF) and the potential therapeutic role of catheter ablation to treat patients who have paroxysmal AF. This initial observation ushered in the modern era of catheter ablation to treat patients who have AF, and tremendous progress has been made in understanding its pathogenesis and the catheter approaches to treating this rhythm. Although the current state of AF catheter ablation is well described earlier in this issue, this article reflects on some of the major unanswered questions about AF management, and the future technological and investigational directions being explored in the nonpharmacologic management of AF.

Original language	English
Pages (from-to)	237-258
Number of pages	22
Journal	Medical Clinics of North America
Volume	92
Issue number	1
DOIs	https://doi.org/10.1016/j.mcna.2007.09.008
State	Published - Jan 2008
Externally published	Yes

Access to Document

10.1016/j.mcna.2007.09.008

Cite this

@article{db1f9bb7c44b43dcb7902d16142ca646,

title = "Atrial Fibrillation: Unanswered Questions and Future Directions",

abstract = "Just more than a decade ago, Haissaguerre and colleagues provided the seminal demonstration of the role of pulmonary vein triggers in the pathogenesis of atrial fibrillation (AF) and the potential therapeutic role of catheter ablation to treat patients who have paroxysmal AF. This initial observation ushered in the modern era of catheter ablation to treat patients who have AF, and tremendous progress has been made in understanding its pathogenesis and the catheter approaches to treating this rhythm. Although the current state of AF catheter ablation is well described earlier in this issue, this article reflects on some of the major unanswered questions about AF management, and the future technological and investigational directions being explored in the nonpharmacologic management of AF.",

author = "Reddy, \{Vivek Y.\}",

note = "Funding Information: This work was supported in part by the Deane Institute for Integrative Research in Atrial Fibrillation and Stroke. Dr. Reddy has received grant support or served as a consultant to Biosense-Webster, Inc., CardioFocus, Inc., Cryocath Technologies Inc., GE Medical Systems, Inc., Hansen Medical, Inc., Philips Medical Systems, Inc., ProRhythm, Inc., St. Jude Medical, Inc., and Stereotaxis, Inc. ",

year = "2008",

month = jan,

doi = "10.1016/j.mcna.2007.09.008",

language = "English",

volume = "92",

pages = "237--258",

journal = "Medical Clinics of North America",

issn = "0025-7125",

publisher = "W.B. Saunders",

number = "1",

}

TY - JOUR

T1 - Atrial Fibrillation

T2 - Unanswered Questions and Future Directions

AU - Reddy, Vivek Y.

N1 - Funding Information: This work was supported in part by the Deane Institute for Integrative Research in Atrial Fibrillation and Stroke. Dr. Reddy has received grant support or served as a consultant to Biosense-Webster, Inc., CardioFocus, Inc., Cryocath Technologies Inc., GE Medical Systems, Inc., Hansen Medical, Inc., Philips Medical Systems, Inc., ProRhythm, Inc., St. Jude Medical, Inc., and Stereotaxis, Inc.

PY - 2008/1

Y1 - 2008/1

N2 - Just more than a decade ago, Haissaguerre and colleagues provided the seminal demonstration of the role of pulmonary vein triggers in the pathogenesis of atrial fibrillation (AF) and the potential therapeutic role of catheter ablation to treat patients who have paroxysmal AF. This initial observation ushered in the modern era of catheter ablation to treat patients who have AF, and tremendous progress has been made in understanding its pathogenesis and the catheter approaches to treating this rhythm. Although the current state of AF catheter ablation is well described earlier in this issue, this article reflects on some of the major unanswered questions about AF management, and the future technological and investigational directions being explored in the nonpharmacologic management of AF.

AB - Just more than a decade ago, Haissaguerre and colleagues provided the seminal demonstration of the role of pulmonary vein triggers in the pathogenesis of atrial fibrillation (AF) and the potential therapeutic role of catheter ablation to treat patients who have paroxysmal AF. This initial observation ushered in the modern era of catheter ablation to treat patients who have AF, and tremendous progress has been made in understanding its pathogenesis and the catheter approaches to treating this rhythm. Although the current state of AF catheter ablation is well described earlier in this issue, this article reflects on some of the major unanswered questions about AF management, and the future technological and investigational directions being explored in the nonpharmacologic management of AF.

UR - https://www.scopus.com/pages/publications/36448971606

U2 - 10.1016/j.mcna.2007.09.008

DO - 10.1016/j.mcna.2007.09.008

M3 - Review article

C2 - 18061007

AN - SCOPUS:36448971606

SN - 0025-7125

VL - 92

SP - 237

EP - 258

JO - Medical Clinics of North America

JF - Medical Clinics of North America

IS - 1

ER -

Atrial Fibrillation: Unanswered Questions and Future Directions

Abstract

Access to Document

Fingerprint

Cite this